• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,130.24 810.69
( 1.11%)
Global Indices
Nasdaq
46,525.67 -61.07
(-0.13%)
Dow Jones
6,603.69 7.37
(0.11%)
Hang Seng
53,576.26 452.77
(0.85%)
Nikkei 225
10,436.29 71.50
(0.69%)
Forex
USD-INR
93.02 -0.15
(-0.16%)
EUR-INR
107.32 -0.65
(-0.60%)
GBP-INR
123.03 -0.78
(-0.63%)
JPY-INR
0.58 0.00
(-0.67%)

EQUITY - MARKET SCREENER

Mahanagar Telephone Nigam Ltd
Industry :  Telecommunications - Service Provider
BSE Code
ISIN Demat
Book Value()
500108
INE153A01019
-457.3346032
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MTNL
0
1540.98
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

vipul ltd
Alembic Pharma receives USFDA approval for Parkinson’s drug tablets
Feb 06,2026
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Stalevo Tablets, manufactured by Orion Corporation. These tablets are indicated for the treatment of Parkinson’s disease.

With this approval, Alembic Pharmaceuticals now has a cumulative total of 234 ANDA approvals from the USFDA, including 214 final approvals and 20 tentative approvals.

Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets.

On the financial front, the company reported a consolidated net profit of Rs 184.71 crore in Q2 FY26, up 20.40% from Rs 153.41 crore in Q2 FY25. Revenue from operations rose 15.90% year-on-year to Rs 1,910.15 crore in the quarter ended September 2025.

Shares of Alembic Pharmaceuticals declined 2.17% to Rs 792.15 on the BSE.